Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome-The ESSICS study

Critical Care Medicine

Volumn 36, Issue 3, 2008, Pages 716-723

  Werdan, Karl ^a   Pilz, Günter ^b   Müller Werdan, Ursula ^a   Enriquez, Monika Maas ^c   Schmitt, Dierk V ^d   Mohr, Friedrich Wilhelm ^d   Neeser, Gertraud ^b   Schöndube, Friedrich ^e   Schäfers, Hans Joachim ^f   Haverich, Axel ^g   Fraunberger, Peter ^h   Andersson, Jan ⁱ   Kreuzer, Eckart ^b   Thijs, Lambert G ^j  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c BAYER AG   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h Medizinisches Zentrallaboratorium GesmbH   (Austria)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j VU UNIVERSITY AMSTERDAM   (Netherlands)

more..

Author keywords

Acute Physiology and Chronic Health Evaluation score; Cardiac surgery; Cytokines; ESSICS study; Immunoglobulin G; Systemic inflammatory response syndrome

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLEEDING; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART DISEASE; HEART FAILURE; HEART SURGERY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PLEURA EFFUSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA; AGED; APACHE; HOSPITALIZATION;

AGED; APACHE; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; SEVERITY OF ILLNESS INDEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 44449133764     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/01.CCM.0B013E3181611F62F     Document Type: Article

References (39)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655
2. Menasche P: The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol 1995;10:597-604
3. Prondzinsky R, Knüpfer A, Loppnow H, et al: Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;129:760-766 (Pubitemid 40487875)
4. Levy JH, Tanaka KA: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:15-20
5. Sablotzki A, Friedrich I, Holzheimer RG, et al: Prophylactic use of immunoglobulins in cardiac surgery. Sepsis 1999;3:247-253
6. Kuhn C, Müller-Werdan U, Schmitt DV, et al: Improved outcome of APACHE II score-defined escalating systemic inflammatory response syndrome in patients post cardiac surgery in 1996 compared to 1988-1990. Eur J Cardiothorac Surg 2000;17:30-37
7. Pilz G, Kääb S, Kreuzer E, et al: Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection 1994;22:8-17 (Pubitemid 24051837)
8. Pilz G, Kreuzer E, Kääb S, et al: Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients [published correction appears in Chest 1994;105:1924].
9. Chest 1994;105:76-82
10. Pilz G, Appel R, Kreuzer E, et al: Comparison of early IgM-enriched immunoglobulin vs. polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 1997;111:419-426
11. Pilz G, Fraunberger P, Appel R, et al: Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Crit Care Med 1996;24:596-600
12. Pilz G, Gurniak T, Bujdoso O, et al: A BASIC program for calculation of APACHE II and Elebute scores and sepsis evaluation in intensive care medicine. Comput Biol Med 1991;21:143-159
13. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829
14. Elebute EA, Stoner HB: The grading of sepsis. Br J Surg 1983;70:29-31
15. Marshall JC, Cook DJ, Christou NV, et al: Multiple Organ Dysfunction Score: A reliable description of a complex clinical outcome. Crit Care Med 1995;23:1638-1652
16. Knaus WA, Wagner DP, Lotring T, et al: The APACHE III prognostic system: Risk reduction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619-1636
17. Vincent J-L, Moreno R, Takala J, et al, on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-710
18. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963
19. Higgins TL, Estafanous FG, Loop FD, et al: ICU admission score for predicting morbidity and mortality risk after coronary artery bypass grafting. Ann Thorac Surg 1997;64:1050-1058
20. Sirio CA, Knaus WA: Application of prognostic scoring in adult intensive care. Curr Opin Anaesth 1990;3:241-244
21. Hoffmann H, Markewitz A, Kreuzer E, et al: Pentoxifylline decreases the incidence of multiple organ failure in patients after major cardio-thoracic surgery. Shock 1998;9:235-240
22. Estafanous FG, Loop FD, Higgins TL, et al: Increased risk and decreased morbidity of coronary artery bypass grafting between 1986 and 1994. Ann Thorac Surg 1998;65:383-389
23. Jakob SM, Rothen HU: Intensive care 1980-1995: Change in patient characteristics, nursing workload and outcome. Intensive Care Med 1997;23:1165-1170
24. Noyez L, Janssen D P B, Vandruten J A M, et al: Coronary bypass surgery: What is changing? Analysis of 3834 patients undergoing primary isolated myocardial revascularisation. Eur J Cardiothor Surg 1998;13:365-369
25. Warner CD, Weintraub WS, Craver JM, et al: Effect of cardiac surgery patient characteristics on patient outcomes from 1981 to 1995. Circulation 1997;96:1575-1579
26. Werdan K, Pilz G, Bujdoso O, et al: Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med 2007;35:2693-2701
27. Nydegger UE, Sturzenegger M: Adverse effects of intravenous immunoglobulin therapy. Drug Safety 1999;21:171-185
28. Vincent J-L: Endpoints in sepsis trials: More than just 28-day mortality? Crit Care Med 2004;32(Suppl):S209-S213
29. Kazatchkine MD, Kaveri SV: Immuno-modulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755
30. Werdan K: Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 2001;7:354-361
31. Bennett-Guerrero E, Ayuso L, Hamilton-Davies C, et al: Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997;277:646-650
32. Norrby-Teglund A, Ihendyane N, Kansal R, et al: Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens. Clin Infect Dis 2000;31:1175-1182
33. Trautmann M, Held TK, Susa M, et al: Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998;111:81-90
34. Andersson JP, Andersson UG: Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990;71:372-376
35. Kaul R, McGeer A, Norrby-Teglund A, et al, and The Canadian Streptococcal Study Group: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-A comparative observational study. Clin Infect Dis 1999;28:800-807
36. Menezes M C S, Bernard G, Sato MN, et al: In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int Arch Allergy Immunol 1997;114:323-328
37. Alejandria MM, Lansang MA, Dans LF, et al: Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Update in 2002. Oxford, UK: Update Software
38. Kress HG, Scheidewig C, Schmitt H, et al Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A-and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med 1999;27:1281-1287;1387-1388
39. ®) after cardiac surgery (ATMI): Outline and preliminary study protocol for discussion. Eur J Surg 1999;163(Suppl 584):26-32